Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital, China Everbright, Alwin Capital, and BioTrack Capital. The funds raised will be directed towards accelerating clinical studies for a thalassemia therapy, as well as research and development of gene therapy and underlying technological innovations.
Clinical Progress and Milestones for Reforgene
Founded in 2019, Reforgene Medicine obtained tacit clinical trial approval for its β-thalassemia drug RM-001 in China in November 2022, with the Phase I study currently underway. The early clinical studies have shown promising results, with all thalassemia patients treated showing complete cure and a return to good health, having resumed their normal lives.
The Impact of Reforgene’s Gene Therapy
Reforgene’s gene editing therapies hold significant potential in the field of genetic medicine, particularly for diseases like thalassemia. The successful fundraising and clinical progress indicate a strong foundation for the company to further develop its therapies and contribute to medical advancements in gene editing and therapeutics.-Fineline Info & Tech
